Entities / Company
ALK-Abelló.
Danish pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 30
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Supply of auto-injectors is facing shortages, coinciding with reports that severe allergies affect 300,000 people in Austria.Some support1 report
-
NICE recommended ALK-Abelló's allergy tablets, which are now available through the National Health Service.Some support1 report
-
ALK-Abelló received approval from Health Canada and launched its product neffy in the Canadian market.Some support1 report
-
ALK-Abelló partnered with ARS Pharma outside the U.S. on July 18, 2025, and gained rights to market EURneffy in the U.K.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around ALK-Abelló this week
News at the entities that move ALK-Abelló most-
Denmark Shared contextUkraine receives military and technical aid from Nordic countries, including radar and satellite communications support.Moves ALK-Abelló
-
National Health Service StructuralMicrosoft 365 service disruption in Hong Kong caused operational delays for healthcare and banking sectors.Moves ALK-Abelló
Connections
The 6 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Edward Jordan Structural
Edward Jordan holds the executive vice president role for ALK North America.
-
Health Canada Structural
Health Canada grants regulatory approval to ALK-Abelló, establishing a formal regulatory dependency for market access.
-
National Health Service Structural
ALK-Abelló supplies products (tablets) that are procured and made available through the National Health Service.
-
NICE formally recommended ALK-Abelló's allergy tablets, influencing their market access in the UK.
-
Denmark Shared context
ALK-Abelló is located and operates within Denmark.
-
Changchun Shared context
ALK-Abelló conducted a Phase 3 clinical trial within the geographic context of China.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
1 eventAugust 2026
3 events- Supply of auto-injectors is facing shortages, coinciding with reports that severe allergies affect 300,000 people in Austria.
- NICE recommended ALK-Abelló's allergy tablets, which are now available through the National Health Service.
- ALK-Abelló received approval from Health Canada and launched its product neffy in the Canadian market.